THEREMIA is a French deeptech company specializing in precision medicine. It has developed an AI-driven platform that personalizes medical treatments based on the specific characteristics of each patient. By adjusting parameters such as the frequency, dosage, and formulation of medications, Theremia aims to improve treatment effectiveness while reducing side effects, a central objective in enhancing patient adherence.
A Crucial Issue in Medical Care
Standard treatments, often developed for typical patient profiles, have significant limitations. Approximately 60% of patients abandon their treatment due to undesirable effects or insufficient results. Theremia addresses this issue by integrating multi-scale AI models that adapt medications to the physiological particularities of individual patients. This personalization helps minimize risks and maximize treatment effectiveness, thereby increasing the likelihood that patients adhere to their treatment plans.
A Robust Scientific Approach
Theremia builds its model on validated methods combining data science, artificial intelligence, and pharmacology. The startup works closely with practitioners specializing in various conditions, particularly those affecting the central nervous system, such as Parkinson’s, Alzheimer’s, depression, and multiple sclerosis. These partnerships continuously refine the algorithms and ensure that the treatments proposed are scientifically sound and tailored to the specific requirements of each disease.
Impact on Drug Developers
In a context where pharmaceutical companies must demonstrate the efficacy of their treatments for specific patient subgroups, Theremia offers a solution that facilitates the collection of real-world data (RWD). By enabling the proof of treatment impact on targeted groups, Theremia supports companies in their “Value-Based Healthcare” approach and helps build trust among regulators, payers, and patients.
A Complementary Leadership Team
Theremia is led by Iris Maréchal, a former BCG consultant with expertise in public health and mathematics, and Chloé Geoffroy, a pharmacist, engineer, and neuroscientist. Together, they manage a team of about ten collaborators, primarily from scientific and technological fields, working on projects focused on optimizing treatments through AI.
Funding to Accelerate Development
Theremia recently raised €3 million in seed funding in a round led by Eurazeo and Salica Investments, with the support of Entrepreneur First, BPIFrance, and notable business angels. This funding aims to strengthen the scientific team and establish partnerships with medical institutes to enhance the treatment personalization algorithm. With these resources, Theremia plans to accelerate its expansion in Europe and become a reference in precision medicine.
